- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01407016
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects
September 27, 2011 updated by: Pfizer
A Phase 1, Open Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Following Single And Multiple Intravenous Infusion In Healthy Japanese Adult Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy Japanese male and/or female subjects.
Exclusion Criteria:
- Subject with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Subject with history of regular alcohol consumption exceeding 7 drink/week for females or 14 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.0
|
On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes.
On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma metronidazole pharmacokinetic parameters for single dose:Cmax
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma metronidazole pharmacokinetic parameters for single dose:AUClast
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma metronidazole pharmacokinetic parameters for single dose:AUC0-6
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma metronidazole pharmacokinetic parameters for single dose:Tmax
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma metronidazole pharmacokinetic parameters for multiple dose:Ctrough
Time Frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
|
prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
|
Plasma metronidazole pharmacokinetic parameters for multiple dose:Cmax
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Plasma metronidazole pharmacokinetic parameters for multiple dose:AUC0-6
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Plasma metronidazole pharmacokinetic parameters for multiple dose:Tmax
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Plasma metronidazole pharmacokinetic parameters for multiple dose:CL
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Cmax
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUClast
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUC0-6
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Tmax
Time Frame: Day 1 to Day 3
|
Day 1 to Day 3
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Ctrough
Time Frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
|
prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Cmax
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: AUC0-6
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Tmax
Time Frame: Day 8 to Day 9
|
Day 8 to Day 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
July 20, 2011
First Submitted That Met QC Criteria
July 29, 2011
First Posted (Estimate)
August 1, 2011
Study Record Updates
Last Update Posted (Estimate)
September 28, 2011
Last Update Submitted That Met QC Criteria
September 27, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A6831006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Vastra Gotaland RegionGöteborg UniversityRecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis InfectionSweden
-
University of ZurichRecruitingProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
Ondine Biomedical Inc.CompletedNosocomial Infection | Surgical Site Infections | Healthcare Associated InfectionsUnited States
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
-
Duke UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedSurgical Site Infection | Infection ControlUnited States
Clinical Trials on metronidazole IV 500 mg
-
HaEmek Medical Center, IsraelUnknown
-
Tulane UniversityUniversity of Alabama at Birmingham; Louisiana State University Health Sciences...Not yet recruiting
-
University Medical Center GroningenCompletedPeriodontal Diseases | Peri-implantitis
-
University of Geneva, SwitzerlandCompletedChronic PeriodontitisSwitzerland
-
University of Geneva, SwitzerlandUniversity of LausanneRecruitingPeriodontal Diseases | Pharmacokinetics | AntibioticsSwitzerland
-
Kaohsiung Veterans General Hospital.CompletedHelicobacter Pylori InfectionTaiwan
-
dr. IJM Han-GeurtsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)RecruitingDrain Abscess | Perianal Abscess | Perianal FistulaNetherlands
-
Taipei Medical UniversityCompleted
-
Centro Universitario de TonaláCompletedDiabetes Mellitus | Periodontitis | Periodontal Pocket
-
Dow University of Health SciencesCompleted